Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine- radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer

Anti-Cancer Drugs

Volumn 22, Issue 2, 2011, Pages 185-190

  Sastre, Javier ^a   Custodio, Ana ^a   Sanchez, Juan C ^a   Ortega, Luis ^a   Rodriguez, Laura ^a   Puente, Javier ^a   Corona, Juan ^a   Alfonso, Rosario ^a   De Las Heras, Manuel ^a   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

adjuvant chemotherapy; rectal cancer; risk adapted

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; VOMITING;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 78650764824     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328340fd02     Document Type: Article

References (23)

1. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal cancer. N Engl J Med 1985; 312:1465-1472.
2. Fisher B,Wolmark N, Rockette H, Redmond C, Deutsch M,Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP Protocol R-01. J Natl Cancer Inst 1988; 80:21-29.
3. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709-715.
4. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638-646.
5. Sauer R, Becker H, Hohenberger W, Rödel C,Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740.
6. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee Sh, Madoff RD, Rotherberg DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated with mesorectal excision. Dis Colon Rectum 2003; 46:298-304.
7. Theodoropoulos G, Wise WE, Padmanabhan A Kerner BA, Taylor CW, Aguilar PS, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45:895-903.
8. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
9. Kuebler JP,Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007; 16:2198-2204.
10. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother and Oncol 2009; 92:148-163.
11. Glimelius B, Oliveira J; On behalf of the ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl):57-60.
12. Gerard J-P, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006; 24:4620-4625.
13. Bosset J-F, Collette L, Calais DG, Mineur L, Maingon Ph, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med 2006; 355:1114-1123.
14. Roth MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27:5124-5130.
15. Gill S, Loprinzi L, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?. J Clin Oncol 2004; 22:1797-1806.
16. Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai W-Y, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24:2368-2375.
17. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-3116.
18. Qua H-M, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113:57-64.
19. Collette L, Bosset J-F, Den Dulk M, Nguyen F, Mineur L, Maingon Ph, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25:4379-4386.
20. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G,Wotherspoon A, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase 2 trial. Lancet Oncology 2010; 11:241-248.
21. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont MJ, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 2010; 28:859-865.
22. Minsky BD. Adjuvant management of rectal cancer: The more we learn, the less we know. J Clin Oncol 2007; 25:4339-4340.
23. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, et al. The diagnosis and management of rectal cancer: Expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 2008; 19 (Suppl):Svi1-Svi8.